

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. Which of the following outcomes was observed in an extended follow-up subgroup analysis evaluating the impact of prior treatment regimens on the efficacy of selinexor, bortezomib and dexamethasone (SvD) for relapsed/refractory (R/R) multiple myeloma (MM) from the Phase III BOSTON trial?**
 - a. SvD did not lead to progression-free survival (PFS) improvement in any patient subgroup examined
 - b. SvD only led to PFS improvement in patients with lenalidomide-refractory disease
 - c. SvD only led to PFS improvements in patients with bortezomib-naïve disease
 - d. SvD led to PFS improvements in all patient subgroups examined
- 2. Results from the Phase I/II MM-002 study evaluating mezigdomide with dexamethasone and either daratumumab or elotuzumab for R/R MM demonstrated which of the following outcomes in the cohort of patients receiving daratumumab?**
 - a. A combined overall response rate (ORR) of 25%
 - b. A combined ORR of nearly 50%
 - c. A combined ORR of nearly 80%
- 3. Updated analysis of the Phase III KarMMa-3 trial of idecabtagene vicleucel (ide-cel) versus standard regimens for triple class-exposed R/R MM resulted in a new FDA indication for ide-cel as which of the following lines of therapy?**
 - a. After 4 or more prior lines of therapy
 - b. After 2 or more prior lines of therapy
 - c. As first-line therapy
 - d. As neoadjuvant therapy
- 4. Long-term efficacy and safety results from the Phase I/II MonumenTAL-1 study of talquetamab for R/R MM indicated which of the following in terms of the duration of patient responses?**
 - a. Responses were short-lived across all cohorts
 - b. Long-term durable responses were only observed in the cohort of patients who received prior T-cell redirection therapy
 - c. Long-term durable responses were observed across all cohorts
- 5. Which of the following drug types best describes the mechanism of action of BMS-989393?**
 - a. BCMA-targeted bispecific antibody
 - b. GPRC5D-targeted bispecific antibody
 - c. BCMA-directed chimeric antigen receptor (CAR) T-cell therapy
 - d. GPRC5D-directed CAR T-cell therapy